Soluble CD30 and cyclosporine in severe atopic dermatitis

International Archives of Allergy and Immunology

Volumn 121, Issue 4, 2000, Pages 324-328

  Caproni, Marzia ^a,b   Salvatore, E ^a   Cardinali, C ^a   Brazzini, B ^a   Fabbri, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Department of Dermatology   (Italy)

Author keywords

Atopic dermatitis; Cyclosporin A; Soluble CD30

Indexed keywords

CD30 ANTIGEN; CYCLOSPORIN A; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN E;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; T LYMPHOCYTE; TH2 CELL;

EID: 0034056512     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024346     Document Type: Article

References (36)

1. Sillevis Smitt JH, Bos JD, Hulsebosch HJ, Krieg SR: In situ immunophenotyping of antigen presenting cells and T cell subsets in atopic dermatitis. Clin Exp Dermatol, 1985;112:149-156.
2. Bruijnzeel-Koomen C, Van Wichen DF, Spry CJF, Venge P, Bruijnzeel PLB: Active participation of eosinophils in patch test reaction to inhalant allergens in patients with atopic dermatitis. Br J Dermatol 1988;118:229-238.
3. Van Der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML: High frequency of IL-4 producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J Invest Dermatol 1991;97:389-394.
4. Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-257.
5. Mosmann TR, Coffman RL: Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
6. Reinhold U, Kukel S, Goeden B, Neuman U, Kreysel HW: Functional characterization of skin-infiltrating lymphocytes in atopic dermatitis. Clin Exp Immunol 1991;86:444-448.
7. Van Reijsen FC, Bruijnzeel-Koomen C, Kalthoff FS, Maggi E, Romagnani S, Westland JKT, Mudde GC: Skin-derived aeroallergen-specific T-cell clones of Th2 phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992;90:184-193.
8. Kagi MK, Wüthrich B, Montano E, Barandun J, Blase K, Walker C: Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals. Int Arch Allergy Immunol 1994;103:332-340.
9. Grewe M, Gyufko K, Schopf E, Krutmann J: Lesional expression of interferon-γ in atopic eczema. Lancet 1994;343:25-26.
10. Ohmen JD, Hanifin Jm, Nickoloff BJ, Rea T, Wyzykowski R, Kim J, Jullien D, et al: Overexpression of IL-10 in atopic dermatitis. Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J Immunol 1995; 154:1956-1963.
11. Romagnani S: The Th2 hypothesis in allergy - 'Eppur si muove!'. ACI Int 1998;10:158-165.
12. Smith C, Davis T, Anderson D, Solam L, Beckman MP, Jerzy R, Dower SK, Cosman D, Goodwin RG: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. FASEB J 1990;248:1019-1023.
13. Del Prete G, De Carli M, Almerigogna F, Daniel KC, D'Elios M, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S: Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81-86.
14. Manetti R, Annunziato F, Biagiotti R, Giudizi MG, Piccini MP, Giannarini L, Sampognaro S, Parronchi P, Vinante F, Pizzolo G, Romagnani S: CD30 expression by CD8+ T cells producing type 2 helper cytokines. Evidence for large numbers of CD8+CD30+ T cell clones in human immunodeficiency virus infection. J Exp Med 1994;180:2407-2412.
15. Del Prete G, De Carli M, D'Elios MM, Daniel KC, Almerigogna F, Alderson M, Smith CA, Thomas E, Romagnani S: CD30-mediated signalling promotes the development of human T helper type 2-like T cells. J Exp Med 1995;182: 1655-1661.
16. Smith CA, Gruss HJ, Davis T, Anderson D, Farrah T, Baker E, Sutherland GR, et al: CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73:1349-1360.
17. Del Prete G, Maggi E, Pizzolo G, Romagnani S: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 1995;16:76-80.
18. Frezzolini A, Paradisi M, Ruffelli M, Cadoni S, De Pità O: Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997;52:106-109.
19. Zonneveld IM, De Rie MA, Beljaaards RC, Van Der Rhee HJ, Wuite J, Zeegelaar J, Bos JD: The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: A comparison of two dosage regimes. Br J Dermatol 1996;135:15-20.
20. Van Joost T, Stolz E, Heule F: Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987;123:166-167.
21. Sowden JM, Berth-Jones J, Ross JS: Double-blind, placebo-controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
22. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-47.
23. Costa C, Rilliet A, Nicolet M, Saurat JH: Scoring atopice dermatitis: The simpler the better? Acta Derm Venereol 1989;69:41-45.
24. Josimovic-Alasevic O, Durkop H, Schwarting R, Backe E, Stein H, Diamantstein T: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 1989;19:157-162.
25. Kapp A, Czech W, Krutmann J, Schopf E: Eosinophil cationic protein in sera of patients with atopic dermatitis. J Am Acad Dermatol 1991;24:555-558.
26. Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G: Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-343.
27. Pizzolo G, Vinante F, Morosato L, Nadali G, Chilosi M, Gandini G, Sinicco A, Raiteri S, Semenzato G, Stein H, Perona G: High serum level of soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS 1994;8:741-745.
28. D'Elios MM, Romagnani P, Scaletti C, Annunziato F, Manghetti M, Mavilia C, Parronchi P, Pupilli C, Pizzolo G, Maggi E, Del Prete GF, Romagnani S: In vivo CD30 expression in human diseases with predominant activation of Th2-like T cells. J Leukoc Biol 1997;61:539-544.
29. Caproni M, Bianchi B, D'Elios M, De Carli M, Amedei A, Fabbri P: In vivo relevance of CD30 in atopic dermatitis. Allergy 1997;52: 1063-1070.
30. Campbell DE, Kemp AS: Cyclosporine restores cytokine imbalance in chilhood atopic dermatitis. J Allergy Clin Immunol 1997;99:857-859.
31. Ross JS, Camp RDR: Cyclosporin A in atopic dermatitis. Br J Dermatol 1990;122:41-45.
32. Granelli-Piperno A: In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporine A. J Exp Med 1988;168:1649-1658.
33. Randak C, Brabletz T, Hergenrother M: Cyclosporin A suppresses the expression of the interleukin 2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer. EMBO J 1990;9:2529-2536.
34. Bottari V, Frezzolini A, Ruffelli M, Puddu P, Fontana L, De Pità O: Cyclosporin A (CyA) reduces sCD30 levels in atopic dermatitis: A possible new immune intervention. Allergy 1999;54:507-510.
35. Caproni M, D'agata A, Cappelli G, Fabbri P: Modulation of serum eosinophil cationic protein levels by Cyclosporin in severe atopic dermatitis. Br J Dermatol 1996;135:336-337.
36. Mori A, Suko M, Nishizaki Y, et al: Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK 506, Cyclosporin A and glucocorticoid. Int Arch Allergy Immunol 1994;104:32-35.